TrialScientific reports2021

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer.

Hazem Ghebeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.